BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Complix N.V.

Headquarters: Diepenbeek, Belgium
Year Founded: 2008
Status: Private

BioCentury | Mar 30, 2022
Product Development

March 29 Quick Takes: Pfizer preps etrasimod submissions after second Phase III readout

Plus Innovent, Lilly expand oncology partnership and updates from InnoRNA, ImmunoGen and more
BioCentury | Jan 11, 2022
Management Tracks

Suliman named CEO of ReCode

Plus Cohen leaving Adaptive as CFO and updates from iTeos, Sorrento and more
BioCentury | Apr 27, 2021
Product Development

I-Mab is pursuing mRNA therapies, eyeing orally delivered antibodies for ‘third wave’ of its immuno-oncology pipeline

mRNA therapeutics and orally delivered antibodies are next on the docket as I-Mab continues to build out the next generation of its immuno-oncology portfolio. “I-Mab’s innovation comes
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

Merck, WuXi BD alum Tong Zhang readies his tool kit to partner assets with roots in China’s hospitals
BioCentury | Mar 10, 2021
Deals

I-Mab signs first two deals of immuno-oncology discovery initiative

I-Mab’s deals with Complix and Shanghai Affinity mark the start of a new discovery initiative to build out the Chinese biotech’s immuno-oncology pipeline.  I-Mab Biopharma
BioCentury | Nov 27, 2018
Distillery Therapeutics

Cancer

BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

BioCentury | Oct 12, 2017
Product R&D

Artificial mini proteins

How Virvio is using artificial mini proteins to treat influenza
Items per page:
1 - 10 of 27
Help Center
Username
Request Training
Submit Data Correction
Ask a Question